Research Use Only
This page is intended for educational and research purposes only. Apex Pep Lab products are not intended for human or animal use.
Summary
CJC-1295 and Ipamorelin are two research peptides often discussed together because they relate to the same general growth hormone signaling system, but through different pathways. CJC-1295 is studied as a modified version of GHRH, a natural signal involved in growth hormone release. Ipamorelin is studied as a compound that interacts with the ghrelin/growth hormone secretagogue receptor pathway. In research settings, the pairing is often discussed because one compound relates to the “release signal,” while the other relates to receptor activation involved in growth hormone signaling.
Overview
CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone. It was designed to extend the activity of GHRH-like signaling by improving pharmacokinetic stability. Ipamorelin is a synthetic pentapeptide that has been described in research literature as a selective growth hormone secretagogue. The combination is commonly discussed in research settings because the two compounds are associated with complementary mechanisms within the somatotropic axis.
Research Background
Published research on CJC-1295 has examined its pharmacokinetic profile, pharmacodynamic activity, and ability to prolong growth hormone and IGF-1 signaling markers in controlled study settings. Research on Ipamorelin has focused on its selectivity as a growth hormone secretagogue and its activity at the ghrelin/growth hormone secretagogue receptor pathway. The combination of GHRH analog activity and GHS receptor activity is the primary reason these two compounds are frequently grouped together in research discussions.
Mechanisms Studied
CJC-1295 is studied in relation to GHRH receptor signaling and downstream growth hormone release. Ipamorelin is studied as a selective agonist of the growth hormone secretagogue receptor, also known as the ghrelin receptor. Research interest often focuses on how these pathways influence pulsatile growth hormone signaling, IGF-1 activity, receptor selectivity, and somatotropic axis regulation.
Published Research Summary
A clinical pharmacology study of CJC-1295 evaluated its pharmacokinetic and pharmacodynamic profile as a long-acting GHRH analog and reported prolonged stimulation of growth hormone and IGF-1 markers in healthy adult subjects. Separate research on Ipamorelin described it as a selective growth hormone secretagogue with GH-release selectivity similar to GHRH. Additional work has examined ghrelin and growth hormone secretagogue receptor biology, which provides important background for understanding Ipamorelin’s research context.
Quality & Verification
For research compounds such as CJC-1295 and Ipamorelin, documentation is important. Researchers commonly review batch-specific Certificates of Analysis, HPLC purity data, mass spectrometry verification, and lot identification to evaluate compound identity, consistency, and analytical quality.
References & Published Research
- Prolonged Stimulation of Growth Hormone and IGF-1 Secretion by CJC-1295, a Long-Acting GHRH Analog
- Once-Daily Administration of CJC-1295, a Long-Acting GHRH Analog, in a GHRH Knockout Mouse Model
- Ipamorelin, the First Selective Growth Hormone Secretagogue
- Growth Hormone-Releasing Peptides and Ghrelin Receptor Pathway Research
- Ghrelin and Growth Hormone Secretagogue Receptor Biology